Iridian Asset Management’s Amgen AMGN Stock Holding History

Iridian Asset Management’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-20,000	Closed	-$2.92M	–	83
2016 Q4	$2.92M	Sell	20,000 -5,000	-20%	-$753K	0.03%	61
2016 Q3	$4.17M	Hold	25,000	–	–	0.04%	54
2016 Q2	$3.8M	Hold	25,000	–	–	0.04%	51
2016 Q1	$3.75M	Hold	25,000	–	–	0.03%	46
2015 Q4	$4.06M	Hold	25,000	–	–	0.03%	46
2015 Q3	$3.46M	Hold	25,000	–	–	0.03%	49
2015 Q2	$3.84M	Buy	+25,000	New	+$4M	0.03%	48

Other funds holding AMGN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Iridian Asset Management's AMGN Position: Q1 2017 in Review

Iridian Asset Management sold out of Amgen (AMGN) in Q1 2017, closing a stake of 20,000 shares — an estimated $2.92M sold.

Iridian Asset Management first reported a position in AMGN in Q2 2015 and held it in 7 quarters. The position peaked at $4.17M in Q3 2016. 1,600 funds tracked by Wall St. Rank hold AMGN as of Q1 2017.

Iridian Asset Management reported no remaining Amgen position as of Q1 2017 after selling out during the quarter.
Iridian Asset Management sold 20,000 Amgen shares in Q1 2017, an estimated $2.92M.
Iridian Asset Management first reported a position in Amgen in Q2 2015 and held it in 7 quarters.
Iridian Asset Management's Amgen position peaked at $4.17M in Q3 2016.
1,600 funds tracked by Wall St. Rank held Amgen as of Q1 2017.

Based on Iridian Asset Management's 13F filing for Q1 2017, filed 9 May 2017.